Intercept Pharmaceuticals Inc
NASDAQ:
ICPT
-
Intercept Pharmaceuticals Inc
-
Sector
Health Care
-
Industry
Biotechnology
-
Company web
Link
-
Employees
Full Time Employees: 456
-
Executives
- Paolo Fundaro
- Mark Pruzanski
- Sandip Kapadia
- Lisa Bright
- Jerome Durso
- David Ford
- Richard Kim
- Rachel McMinn
- David Shapiro
- Srinivas Akkaraju
-
Company address
- 450 West 15th Street, Suite 505, Floor 5
- New York, NY 10011
- United States of America
- 1-646-747-1000
-
Investor Relation Site
Link
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Intercept Pharmaceuticals Inc: Slide deck
- ICPT - Q3 Earnings Presentation 1 Nov 2017: Slides deck
- ICPT - Q2 Earnings Presentation 31 July 2017: Slides deck
- ICPT - Q1 Earnings Presentation 4 May 2017: Slides deck
- ICPT - Q4 Earnings Presentation 23 Feb 2017: Slides deck
- ICPT - Q3 Earnings Presentation 3 Nov 2016: Slides deck
- ICPT - Q1 Earnings Presentation 5 May 2016: Slides deck